Imfinzi

Active substance

durvalumab

Holder

AstraZeneca

Status

Closed

Indication

treatment of locally advanced (stage III), unresectable non-small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum-based chemoradiation therapy

Public documents

Approbation

Information for the patient

Informed consent

Last update

03/05/2019